Teclistamab
Teclistamab is a bispecific antibody that targets BCMA (B-cell maturation antigen) and CD3, facilitating the immune system's ability to attack multiple myeloma cells. It represents a novel approach in cancer immunotherapy, potentially enhancing immune response against cancer cells, which is crucial for improving longevity and health outcomes in patients with multiple myeloma.
Member access required
Clinical protocols and outcomes data are available to AXIFI Members and Providers.